These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21951751)

  • 1. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.
    Pilotte AP; Hohos MB; Polson KM; Huftalen TM; Treister N
    Clin J Oncol Nurs; 2011 Oct; 15(5):E83-9. PubMed ID: 21951751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
    Sonis S; Treister N; Chawla S; Demetri G; Haluska F
    Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin inhibitor-associated stomatitis.
    Boers-Doets CB; Raber-Durlacher JE; Treister NS; Epstein JB; Arends AB; Wiersma DR; Lalla RV; Logan RM; van Erp NP; Gelderblom H
    Future Oncol; 2013 Dec; 9(12):1883-92. PubMed ID: 24295418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
    Chambers MS; Rugo HS; Litton JK; Meiller TF
    J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical presentation and management of mTOR inhibitor-associated stomatitis.
    de Oliveira MA; Martins E Martins F; Wang Q; Sonis S; Demetri G; George S; Butrynski J; Treister NS
    Oral Oncol; 2011 Oct; 47(10):998-1003. PubMed ID: 21890398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
    Peterson DE; O'Shaughnessy JA; Rugo HS; Elad S; Schubert MM; Viet CT; Campbell-Baird C; Hronek J; Seery V; Divers J; Glaspy J; Schmidt BL; Meiller TF
    Cancer Med; 2016 Aug; 5(8):1897-907. PubMed ID: 27334013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
    Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
    Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nursing care for oral complications associated with chemotherapy. A survey among members of the Dutch Oncology Nursing Society.
    Nieweg R; van Tinteren H; Poelhuis EK; Abraham-Inpijn L
    Cancer Nurs; 1992 Oct; 15(5):313-21. PubMed ID: 1423250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the incidence of stomatitis using a quality assessment and improvement approach.
    Graham KM; Pecoraro DA; Ventura M; Meyer CC
    Cancer Nurs; 1993 Apr; 16(2):117-22. PubMed ID: 8477399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of assessment rating scales for chemotherapy-induced oral mucositis.
    Jaroneski LA
    Oncol Nurs Forum; 2006 Nov; 33(6):1085-90; quiz 1091-3. PubMed ID: 17149392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy: the effect of oral cryotherapy on the development of mucositis.
    Karagözoğlu S; Filiz Ulusoy M
    J Clin Nurs; 2005 Jul; 14(6):754-65. PubMed ID: 15946284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.
    Kalogirou EM; Tosios KI; Piperi EP; Sklavounou A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e13-9. PubMed ID: 25442249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing and managing chemotherapy-induced mucositis pain.
    Harris DJ; Knobf MT
    Clin J Oncol Nurs; 2004 Dec; 8(6):622-8. PubMed ID: 15637957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stomatitis: an overview: protecting the oral cavity during cancer treatment.
    Brown CG; Yoder LH
    Am J Nurs; 2002 Apr; 102 Suppl 4():20-3; quiz 49-52. PubMed ID: 11953533
    [No Abstract]   [Full Text] [Related]  

  • 17. Current trends in managing oral mucositis.
    Cawley MM; Benson LM
    Clin J Oncol Nurs; 2005 Oct; 9(5):584-92. PubMed ID: 16235585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa.
    Sonis S; Andreotta PW; Lyng G
    Oral Dis; 2017 Apr; 23(3):347-352. PubMed ID: 27896917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of oral mucositis in adult and pediatric oncology patients: an evidence-based approach.
    Farrington M; Cullen L; Dawson C
    ORL Head Neck Nurs; 2010; 28(3):8-15. PubMed ID: 20863028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
    Lo Muzio L; Arena C; Troiano G; Villa A
    Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.